In vitro experiments utilizing anti-angiopoietin-2 neutralizing antibodies have demonstrated a decrease in GBM motility, providing further evidence of enhanced GBM invasiveness facilitated by oligodendrocytes. The gene discussed is ANGPT2; the disease is glioblastoma.